Youcef Mehellou

24PUBLICATIONS
9CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursPharmaceutical delivery technologiesToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Oct 03, 2026
Insights into the Mechanism of Action of Phosphoantigen Prodrugs on Vγ9Vδ2 T Cell Activation.

|Mar 20, 2025
Oxidative Stress-Responsive 1 Kinase Catalytic Activity Promotes Triple Negative Breast Cancer Oncogenic Potential.

Azeza M Fdel, Loren Waters, Ira Sharma

|Jul 19, 2024
Phosphonodiamidate prodrugs of phosphoantigens (ProPAgens) exhibit potent Vγ9/Vδ2 T cell activation and eradication of cancer cells.

Qin Xu, Maria Sharif, Edward James

|Jul 19, 2023
Parkinson's Disease: Are PINK1 Activators Inching Closer to the Clinic?

Youcef Mehellou

|May 30, 2023
PINK1-Dependent Mitophagy Inhibits Elevated Ubiquitin Phosphorylation Caused by Mitochondrial Damage.

Olivia A Lambourne, Shane Bell, Léa P Wilhelm

|Nov 04, 2021
Aryloxy Pivaloyloxymethyl Prodrugs as Nucleoside Monophosphate Prodrugs.

Ashwag S Alanazi, Ageo Miccoli, Youcef Mehellou

Pageof 4

Frequent Collaborators

6 joint publications

Benjamin E Willcox

2 joint publications

Martin S Davey

1 joint publications

Cécile S Le Duff

1 joint publications

Fiyaz Mohammed